115 results on '"Alzheimer’s Disease Neuroimaging Initiative"'
Search Results
2. Visit-To-Visit Blood Pressure Variability and Subthreshold Depressive Symptoms in Older Adults.
3. Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia.
4. Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia.
5. Assessing the Clinical Meaningfulness of the Alzheimer's Disease Composite Score (ADCOMS) Tool.
6. β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
7. Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
8. Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
9. Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
10. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
11. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
12. Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults.
13. Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
14. White matter atrophy in cerebral amyloid angiopathy.
15. Bilateral Distance Partition of Periventricular and Deep White Matter Hyperintensities: Performance of the Method in the Aging Brain.
16. Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy.
17. Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration.
18. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
19. Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease.
20. Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study.
21. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation.
22. Association of amyloid-β CSF/PET discordance and tau load 5 years later.
23. Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
24. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults.
25. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease.
26. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
27. Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypes.
28. Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.
29. Statin Use and Risk of Cognitive Decline in the ADNI Cohort.
30. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.
31. Association Between Neuropsychiatric Symptom Trajectory and Conversion to Alzheimer Disease.
32. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration.
33. Type 2 Diabetes Interacts With Alzheimer Disease Risk Factors to Predict Functional Decline.
34. Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI.
35. ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia.
36. VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD.
37. Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory.
38. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
39. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.
40. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?
41. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
42. Effects of Normative Adjustments to the Montreal Cognitive Assessment.
43. Dissociable influences of ε4 and polygenic risk of AD dementia on amyloid and cognition.
44. Memory decline accompanies subthreshold amyloid accumulation.
45. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.
46. Neurogranin as a predictor of memory and executive function decline in MCI patients.
47. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
48. In vivo staging of regional amyloid deposition.
49. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
50. genotype and early β-amyloid accumulation in older adults without dementia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.